Philadelphia Inquirer Profiles HIV Vaccine Researcher Hildegund Ertl
The Philadelphia Inquirer today profiles Hildegund Ertl, a vaccine researcher at Philadelphia's Wistar Institute. Ertl is developing a vaccine to prevent HIV infection that uses pieces of the virus' genetic code and a specific type of adenovirus, which normally causes colds but can be modified to be harmless. The adenovirus carries the pieces of HIV genes into the body, where the immune system mounts a defense against the proteins and prepares for a true invasion of HIV. Ertl is also working on vaccines against human papillomavirus and Ebola (Flam, Philadelphia Inquirer, 6/10). The full article is available online.This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.